{"schema_version":"secwatch.filing_event.v1","accession":"0001804220-24-000015","form_type":"8-K","ticker":"REGN","cik":"0000872589","company_name":"REGENERON PHARMACEUTICALS, INC.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.227726+00:00","generated_at":"2026-06-03T01:21:27.861965+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Regeneron Q1 revenue down 1% to $3.15B; Non-GAAP EPS $9.55; new $3B buyback","bullets":["GAAP net income $722M ($6.27 diluted EPS) vs $818M ($7.17) YoY; Non-GAAP net income $1,116M ($9.55).","Dupixent global net sales up 24% to $3.08B; EYLEA HD U.S. sales $200M, total EYLEA/HD $1.4B (down 2%).","Libtayo global net sales up 45% to $264M; Sanofi collaboration revenue up 14% to $910M.","Board authorized new $3.0B share repurchase; Q1 repurchases $298M, $1.2B remaining under prior program.","2024 guidance updated: GAAP R&D $4.92-5.17B, GAAP SG&A $2.94-3.09B; gross margin unchanged."],"urls":{"canonical":"https://secwatch.observer/filing/0001804220-24-000015","json":"https://secwatch.observer/filing/0001804220-24-000015.json","markdown":"https://secwatch.observer/filing/0001804220-24-000015.md","text":"https://secwatch.observer/filing/0001804220-24-000015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872589/000180422024000015/0001804220-24-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872589/000180422024000015/regn-20240502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T01:21:27.861965+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"94ed913b0d4c5b6ce4c03f22eed710417df544ea","claim":"REGENERON PHARMACEUTICALS, INC. reported financial results for first quarter of 2024.","evidence_excerpt":"On May 2, 2024, Regeneron Pharmaceuticals, Inc. issued a press release announcing its financial and operating results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/872589/000180422024000015/0001804220-24-000015-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}